There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...
For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...
CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.
MedPage Today on MSN
Bubbles of Prostate Cancer Info; Cancer Drug Tops Moneymakers; Small Kidney Tumors
News, features, and commentary about cancer-related issues ...
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results